

Osteoporosis Medications Marketed in Canada (June 2023)

For complete details on PharmaCare coverage of medications for Osteoporosis in British Columbia, please see the PharmaCare Special Authority website.

Generic name, brand name, available strengths ¹	Health Canada Osteoporosis Indications ¹	Dosage and annual cost ²		PharmaCare coverage ³
BISPHOSPHONATES				
alendronate		5 mg PO once a day	\$410	non benefit
FOSAMAX, generics 5, 10, 70 mg tabs alendronate + vitamin D3 FOSAVANCE, generics 70 mg/2800, 70 mg/5600 IU tabs	Postmenopausal womenMenGlucocorticoid induced osteoporosis	10 mg PO once a day	\$160	Limited Coverage
		70 mg PO once a week	\$100	
		70 mg/5600 IU PO once a week	\$115	
		70 mg/2800 IU PO once a week	\$210	non benefit
risedronate ACTONEL, ACTONEL DR, generics 5, 35, 150 mg tabs 35 mg delayed-release (DR) tabs	Postmenopausal womenMenGlucocorticoid induced osteoporosis	5 mg PO once a day	\$695	Limited Coverage
		35 mg PO once a week	\$95	
		35 mg DR PO once a week	\$565	non benefit
		150 mg PO once a month	\$530	
zoledronic acid ACLASTA, generics 5 mg/100 mL vial	Postmenopausal womenMenGlucocorticoid induced osteoporosis	5 mg IV infusion once a year	\$365	Limited Coverage
DENOSUMAB rank ligand inhib	pitor			
denosumab PROLIA 60 mg/mL single prefilled syringe	 Postmenopausal women Men Glucocorticoid induced osteoporosis Nonmetastatic breast cancer receiving adjuvant aromatase inhibitor therapy Nonmetastatic prostate cancer receiving androgen deprivation therapy 	60 mg subcut every 6 months	\$910	Limited Coverage
RALOXIFENE selective estroge	n receptor modulator			
raloxifene EVISTA, generics 60 mg tabs	 Postmenopausal women 	60 mg PO once a day	\$405	Limited Coverage
TERIPARATIDE synthetic parat	hyroid hormone			
teriparatide FORTEO, generics OSNUVO biosimilar 250 mcg/mL multidose prefilled pen or cartridge (28 doses)	Postmenopausal womenMenGlucocorticoid induced osteoporosis	20 mcg subcut once a day maximum treatment: 24 months	\$7960	non benefit
ROMOSOZUMAB sclerostin in	hibitor			
romosozumab EVENITY 105 mg single prefilled syringe	 Postmenopausal women 	210 mg subcut once a month maximum treatment: 12 months	\$8515	non benefit

administration calculated from McKesson Canada https://www.mckesson.ca/ (accessed May 2, 2023); ³BC PharmaCare Formulary https://pharmacareformularysearch.gov.bc.ca/